Health Technology Assessment on Sildenafil as Treatment of Pulmonary Arterial Hypertension

Sildenafil is a treatment option for PAH patients that is found to offer an additional 1-3 life years gained       for PAH patients compared to beraprost, currently the only treatment available in the benefit package under the National Social Health Insurance (Jaminan Kasehatan Nasional - JKN) of Indonesia. Off-label use of sildenafil for treatment of PAH is recommended to be included in the benefit package. The study results indicate that there...